A phase I, open label study of single-agent AT 101 in patients with previously untreated, early stage chronic lymphocytic leukemia
Latest Information Update: 20 Jan 2006
Price :
$35 *
At a glance
- Drugs AT 101 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 20 Jan 2006 New trial record.